ArticleBritish journal of clinical pharmacology2026
The decline of 6-thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The decline of 6-thioguanine nucleotides is not linked to impaired efficacy or safety of thiopurines in pregnant women with inflammatory bowel disease.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThiopurines are used to maintain remission in inflammatory bowel disease (IBD). These drugs are metabolized into 6-thioguanine nucleotides (6-TGN), associated with efficacy, and 6-methylmercaptopurine ribonucleotides (6-MMPR), associated with adverse drug reactions. Pregnancy has been linked to a shift in thiopurine metabolism, characterized by reduced 6-TGN and increased 6-MMPR levels. The clinical impact of these changes remains unclear. To explore the association between changes in 6-TGN and 6-MMPR levels with disease activity and toxicity markers in women with IBD during pregnancy.
methodsThis retrospective cohort study included pregnant women with IBD who used thiopurines from six Dutch hospitals (2017-2022). Linear mixed-effects models were used to model changes of 6-TGN and 6-MMPR before, during and after pregnancy, and to identify associations with markers of disease activity (faecal calprotectin) and toxicity (alanine aminotransferase [ALT], leukocytes, platelets).
resultsA total of 87 women with 100 pregnancies were included (64.4% Crohn's disease, 32.2% ulcerative colitis). A significant reduction in 6-TGN was found in the second and third trimester, but no associations with changes in faecal calprotectin were detected. There were no significant increases in 6-MMPR. Increases in 6-MMPR were associated with modest elevations in ALT, but none of the other toxicity markers. Transient thrombocytopenia and leukopenia occurred thrice, and elevated liver enzymes were observed in nine pregnancies.
conclusionsAlthough 6-TGN levels decreased during pregnancy, these fluctuations were not associated with increased disease activity or toxicity. No significant increase in 6-MMPR levels was observed. Proactive monitoring may therefore not be warranted in the pregnant population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.